IMMU - Immunomedics, Inc.
17.44 0.00 (0.00%)
After hours: 5:07PM EDT
| Previous Close | 17.32 |
| Open | 17.25 |
| Bid | 17.43 x 3100 |
| Ask | 17.58 x 1300 |
| Day's Range | 16.92 - 17.45 |
| 52 Week Range | 11.55 - 24.99 |
| Volume | 1,684,465 |
| Avg. Volume | 2,023,654 |
| Market Cap | 3.348B |
| Beta (3Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.45 |
- ACCESSWIRE
SHAREHOLDER ALERT: Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Immunomedics Shareholders to Contact the Firm
HENDERSONVILLE, TN / ACCESSWIRE / September 16, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, announces that purchasers of ...
- Zacks
Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- GlobeNewswire
Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress
Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host an Investor Event on Saturday, September 28, 2019 at 6:30 p.m. Central European Summer Time in Barcelona, Spain, during the Congress 2019. The event will feature presentations by key opinion leaders including Scott Tagawa, M.D., MS, Richard A. Stratton Associate Professor in Hematology & Oncology, Associate Professor of Medicine & Urology, Weill Cornell Medicine, and Associate Attending Physician, NewYork-Presbyterian – Weill Cornell Medical Center, who will present the interim results from TROPHY-U-01 at the Congress. Cora N. Sternberg, M.D., FACP, Clinical Director, Englander Institute for Precision Medicine and Professor of Medicine in Hematology & Oncology, Weill Cornell Medicine and NewYork-Presbyterian will discuss the implications of these data in an evolving metastatic urothelial cancer landscape.
- Zacks
Why Is Immunomedics (IMMU) Down 13.1% Since Last Earnings Report?
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (Other OTC: MGTI), First American Financial Corporation (FAF), Immunomedics, Inc. (IMMU), and AAC Holdings, Inc. (AAC) on behalf of long-term stockholders. Bragar Eagel and Squire is investigating certain officers and directors of MGT Capital Investments following a class action complaint that was filed against MGT Capital on October 9, 2018. The complaint alleges that throughout the class period, defendants made materially false and misleading statements regarding the company's business, operational and compliance policies.
- GlobeNewswire
Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its TROPHY-U-01 late-breaking abstract on interim results of sacituzumab govitecan in patients with metastatic urothelial cancer (mUC) has been selected for oral presentation at the ESMO 2019 Annual Congress, taking place from September 27 to October 1, 2019, at the Fira Barcelona, Spain. “We look forward to presenting, for the first time, interim data for sacituzumab govitecan in metastatic urothelial cancer patients who are relapsed or refractory to platinum-based and checkpoint inhibitor therapies,” commented Dr. Behzad Aghazadeh, Executive Chairman.
- Business Wire
Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between August 23, 2018 and December 20, 2018.
- GlobeNewswire
Immunomedics to Participate in Upcoming Healthcare Conferences
Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.
Motley FoolImmunomedics, Inc. (IMMU) Q2 2019 Earnings Call Transcript
IMMU earnings call for the period ending June 30, 2019.
- Thomson Reuters StreetEvents
Edited Transcript of IMMU earnings conference call or presentation 7-Aug-19 9:00pm GMT
Q2 2019 Immunomedics Inc Earnings Call
- Zacks
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
- GlobeNewswire
Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update
ASCENT Study Reached Target Patient Enrollment First Patients Dosed in TROPICS-02 Study in HR+/HER2– Metastatic Breast Cancer Trop-2-Enriched TROPICS-03 Basket Study Initiated.
- GlobeNewswire
Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019
Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, August 7, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.
- Schaeffer's Investment Research
Drug Stock With Cheap Options Sounds Bear Signal
Short-term options are pricing in low volatility expectations right now
- TipRanks
3 Hot Insider Trading Stocks To Boost Your Portfolio
Actions speak louder than words, as the saying goes. And when it comes to insiders, that certainly seems to be the case. If we track informative insider buy transactions, we can get an idea of the stocks that insiders see as compelling investing opportunities right now. As insiders have access to a wealth of company information, these insights can be very valuable when deciding which stocks to buy or sell. With that in mind we took a closer look at three stocks insiders are snapping up right now: Immunomedics (IMMU)Immunomedics focuses on the development of antibody-drugs for the treatment of cancer. Most notably sacituzumab has received Breakthrough Therapy designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who failed previous therapies. It’s also granted the drug fast track designation for lung cancer treatment. Shares have surged 12% in the last five days, and that’s partly down to an influx of insider money. Most notably, corporate director and owner venBio Select Advisor LLC recently picked up a whopping $13.5 million worth of stock. That brings venBio’s total holding of IMMU to just over $298 million. And it’s not just insiders that are bullish. The stock also shows a ‘Strong Buy’ analyst consensus with an average price target of $23- indicating that further upside potential of 54% lies ahead. “As we expect sacituzumab to address a major unmet need in the treatment of r/r mTNBC [metastatic triple negative breast cancer] next year, we continue to think that IMMU is undervalued for its potential” comments Cowen & Co analyst Phil Nadeau. “We continue to expect sacituzumab will become a standard mTNBC treatment upon its approval” the analyst added. He notes that Daiichi’s DS-1062a has the potential to be long-term competition to IMMU's sacituzumab- but reassures investors that IMMU is clearly well ahead. “Given sacituzumab's several-year lead, it will be incumbent upon DS-1062a to show meaningful advantages in order to displace it” the analyst writes. Fastly Inc (FSLY)Cloud computing services provider Fastly is a newcomer to the markets. The company, which helps companies deliver online content more quickly, debuted on the NYSE back in May. Its IPO was a great success; the company sold 11.25 million shares at $16 each, bringing returns of $180 million. Since the IPO shares have surged to the current price of $20.55.And now we can see that insiders are already pouring more money into this fast-growing tech stock. Abdiel Capital Management, one of the company’s owners, has just picked up a further $7.62 million of FSLY stock. This brings the total holding to $78.8 million. No doubt this move would make sense to five-star analyst Brad Reback of Stifel Nicolaus. He initiated coverage of the stock with a buy rating and $25 price target (22% upside potential). The analyst contends: “In the coming years, we believe Fastly can leverage its superior technological approach to drive continued strong net new customer additions and expand its wallet share among its existing installed base.” Combined with a large market opportunity and the ability to further penetrate international markets, Reback is confident that Fastly can sustain at least a 30% top-line growth profile. Myovant Sciences (MYOV)Myovant Sciences is a clinical-stage biopharma developing therapies for women’s health and endocrine diseases. Shares have crashed 47% year-to-date, with the selloff prompted by the release of relugolix phase 3 uterine fibroids data. Investors are concerned about Abbvie’s (ABBV) uterine fibroid rival, Orlissa.However, insiders are demonstrating their confidence in the company. In the last three months insiders have bought a whopping $160 million of shares. That includes a $45,000 purchase from director Sebelius Kathleen, as well as $20 million from owner Viking Global Investors. Indeed, all ten transactions in the last month are positive insider buy transactions- with only one insider sell transaction recorded four months ago.Furthermore, the Street is also staying onside. All five analysts covering the stock rate Myovant a ‘buy.’ That gives the stock its ‘Strong Buy’ analyst consensus. Meanwhile their average price target of $26 indicates massive upside potential of 194%. Analysts argue that the stock looks oversold at current levels, with Barclays analyst Geoffrey Meacham saying he still believes Myovant’s relugolix has a favorable profile compared to rival offerings. Meanwhile five-star Evercore ISI analyst Ravi Mehrotra is anticipating revenues of $944M for relugolix by 2023 due to its "commercial advantage of a one-a-day pill." Discover more Hot Insider Trading Stocks here
- Simply Wall St.
Are Insiders Buying Immunomedics, Inc. (NASDAQ:IMMU) Stock?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Benzinga
Notable Insider Buys This Past Week: AbbVie, MGM and More
Health care companies featured prominently in the week's insider purchases. MGM Resorts International (NYSE: MGM) had a director continue to make indirect share purchases this past week. MGM stock rose about 2% in the past week, while the S&P 500 was essentially flat.
- Benzinga
Notable Insider Buys This Past Week: American Airlines, MGM and More
Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. MGM Resorts International (NYSE: MGM) saw a director making indirect share purchases this past week.
- TheStreet.com
2 Biotech Names See Directors Direct Cash to Their Shares
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
- Thomson Reuters StreetEvents
Edited Transcript of IMMU earnings conference call or presentation 9-May-19 12:00pm GMT
Q1 2019 Immunomedics Inc Earnings Call
- Associated Press
Immunomedics: 1Q Earnings Snapshot
The Morris Plains, New Jersey-based company said it had a loss of 46 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire
Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of.
- GlobeNewswire
Immunomedics To Participate In Upcoming Healthcare Conferences
Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.
- GlobeNewswire
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, May 9, 2019 at 8:00 a.m. Eastern Time to discuss financial results for the first quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.
